CLINICAL_TRIALS
trial_result
· 2012-08-22
Clinical Trial Update: CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse [Phase 2]
Summary
Pfizer completed a Phase 2 trial of CMA-676 for treating patients with acute myeloid leukemia in first relapse.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Leukemia | Phase 2 | Status: COMPLETED